US5446177A
(en)
*
|
1984-12-28 |
1995-08-29 |
Alcon Laboratories, Inc. |
Anti-inflammatory compounds for ophthalmic use
|
US4686214A
(en)
*
|
1985-10-30 |
1987-08-11 |
Alcon Laboratories, Inc. |
Anti-inflammatory compounds for ophthalmic use
|
US4914090A
(en)
*
|
1985-11-01 |
1990-04-03 |
Schering Corporation |
Ophthalmic compositions
|
IL79661A
(en)
*
|
1986-08-08 |
1991-01-31 |
Yeda Res & Dev |
Antiviral composition containing hypericin or pseudohypericin
|
US4808610A
(en)
*
|
1986-10-02 |
1989-02-28 |
Schering Corporation |
Mometasone furoate anti-inflammatory cream composition using hexylene glycol
|
US4775529A
(en)
*
|
1987-05-21 |
1988-10-04 |
Schering Corporation |
Steroid lotion
|
UA26230A
(uk)
*
|
1990-03-02 |
1999-07-19 |
Глексо Груп Лімітед |
Іhгалятор для спільhого використаhhя з лікувальhим блоком і лікувальhий блок
|
HU213221B
(en)
|
1990-03-02 |
1997-03-28 |
Glaxo Group Ltd |
Inhalation device and medicine packet for device
|
US6536427B2
(en)
|
1990-03-02 |
2003-03-25 |
Glaxo Group Limited |
Inhalation device
|
AU663471B2
(en)
*
|
1990-09-10 |
1995-10-12 |
Merck Sharp & Dohme Corp. |
Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
|
US5474759A
(en)
†
|
1991-06-10 |
1995-12-12 |
Schering Corporation |
Non-chlorofluorocarbon aerosol formulations
|
ATE203900T1
(de)
|
1991-06-10 |
2001-08-15 |
Schering Corp |
Fluorchlorkohlenwasserstofffreie aerosolformulierungen
|
US6127353A
(en)
*
|
1991-09-06 |
2000-10-03 |
Schering Corporation |
Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
|
US5420120A
(en)
*
|
1993-12-17 |
1995-05-30 |
Alcon Laboratories, Inc. |
Anti-inflammatory glucocorticoid compounds for topical ophthalmic use
|
ES2221928T3
(es)
*
|
1993-12-21 |
2005-01-16 |
Schering Corporation |
Pomadas que comprenden furoato de mometasona y acido salicilico para el tratamiento topico de la psoriasis.
|
US5837699A
(en)
*
|
1994-01-27 |
1998-11-17 |
Schering Corporation |
Use of mometasone furoate for treating upper airway passage diseases
|
PE44995A1
(es)
|
1994-01-27 |
1995-12-18 |
Schering Corp |
Furoato de mometasona para el tratamiento de las enfermedades pulmonares y de las vias respiratorias
|
US5502076A
(en)
*
|
1994-03-08 |
1996-03-26 |
Hoffmann-La Roche Inc. |
Dispersing agents for use with hydrofluoroalkane propellants
|
DE4433374A1
(de)
*
|
1994-09-20 |
1996-03-21 |
Hoechst Ag |
17-Desoxi-corticosteroid-21-/O/-Carbonsäure- ester, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
|
US5696105A
(en)
*
|
1996-03-14 |
1997-12-09 |
Hackler; Walter A. |
Antifungal nail composition
|
NZ333410A
(en)
*
|
1996-06-28 |
2000-06-23 |
Schering Corp |
Process for the preparation of 17-esters of 9alpha,21-dihalo-pregnane-11beta,17alphadiol-20-ones
|
US5886200A
(en)
*
|
1996-07-01 |
1999-03-23 |
Schering Corporation |
Process for the preparation of 17-esters of 9 α, 21-dihalo-pregnane-11 β, 17 α-diol-20-ones
|
US6503537B2
(en)
|
1997-03-20 |
2003-01-07 |
Schering Corporation |
Preparation of powder agglomerates
|
US6495167B2
(en)
|
1997-03-20 |
2002-12-17 |
Schering Corporation |
Preparation of powder agglomerates
|
US6297227B1
(en)
|
1998-09-10 |
2001-10-02 |
Schering Corporation |
Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
|
US8722668B2
(en)
*
|
1998-12-23 |
2014-05-13 |
Daryl W. Hochman |
Methods and compositions for the treatment of neuropathic pain and neuropsychiatric disorders
|
PT102343B
(pt)
*
|
1999-08-02 |
2003-11-28 |
Hovione Farmaciencia Sa |
Processo para a preparacao de furoato mometasona
|
PT102405A
(pt)
*
|
2000-01-20 |
2001-07-31 |
Hovione Farmaciencia Sa |
Processo para a preparacao de mometasona
|
GB0009609D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Therapeutic compositions
|
GB0009612D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Therapeutic formulations
|
GB0009605D0
(en)
*
|
2000-04-18 |
2000-06-07 |
Glaxo Group Ltd |
Medicaments
|
GB0015876D0
(en)
*
|
2000-06-28 |
2000-08-23 |
Novartis Ag |
Organic compounds
|
US20020076382A1
(en)
*
|
2000-08-04 |
2002-06-20 |
Kaplan Leonard W. |
Formulations of mometasone and a bronchodilator for pulmonary administration
|
US6787532B2
(en)
|
2000-08-05 |
2004-09-07 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivatives
|
US6858593B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
US6858596B2
(en)
|
2000-08-05 |
2005-02-22 |
Smithkline Beecham Corporation |
Formulation containing anti-inflammatory androstane derivative
|
US6777399B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
NZ523958A
(en)
*
|
2000-08-05 |
2004-11-26 |
Glaxo Group Ltd |
17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derviative as anti-inflammatory agents
|
US6750210B2
(en)
|
2000-08-05 |
2004-06-15 |
Smithkline Beecham Corporation |
Formulation containing novel anti-inflammatory androstane derivative
|
US6759398B2
(en)
*
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
GB0019172D0
(en)
*
|
2000-08-05 |
2000-09-27 |
Glaxo Group Ltd |
Novel compounds
|
US6777400B2
(en)
|
2000-08-05 |
2004-08-17 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative compositions
|
UA77656C2
(en)
|
2001-04-07 |
2007-01-15 |
Glaxo Group Ltd |
S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent
|
MY137522A
(en)
|
2001-04-30 |
2009-02-27 |
Glaxo Group Ltd |
Novel anti-inflammatory androstane derivatives.
|
ES2307751T3
(es)
*
|
2001-06-12 |
2008-12-01 |
Glaxo Group Limited |
Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
|
GB0125259D0
(en)
*
|
2001-10-20 |
2001-12-12 |
Glaxo Group Ltd |
Novel compounds
|
WO2003042229A1
(en)
*
|
2001-11-12 |
2003-05-22 |
Glaxo Group Limited |
Non-aromatic heterocyclic esters of furan-2-one-esters of 17.beta.-carboxyl or 17.beta.-carbothio glucocorticoids
|
GB0127160D0
(en)
*
|
2001-11-12 |
2002-01-02 |
Glaxo Group Ltd |
Novel compounds
|
ITMI20020148A1
(it)
*
|
2002-01-29 |
2003-07-29 |
Nicox Sa |
Nuovi corticosteroidi
|
US20050175545A1
(en)
*
|
2002-02-04 |
2005-08-11 |
Keith Biggadike |
Formulation for inhalation comprising a glucocorticoid and a beta 2-adrenoreceptor agonist
|
GB0202635D0
(en)
*
|
2002-02-05 |
2002-03-20 |
Glaxo Wellcome Mfg Pte Ltd |
Formulation containing novel anti-inflammatory androstane derivative
|
GB0207906D0
(en)
|
2002-04-05 |
2002-05-15 |
3M Innovative Properties Co |
Formoterol and mometasone aerosol formulations
|
GB2389530B
(en)
|
2002-06-14 |
2007-01-10 |
Cipla Ltd |
Pharmaceutical compositions
|
JP2006523674A
(ja)
*
|
2003-04-18 |
2006-10-19 |
ファルマシア・アンド・アップジョン・カンパニー・エルエルシー |
慢性閉塞性肺疾患(copd)のための組合せ治療法
|
BRPI0413330A
(pt)
*
|
2003-08-29 |
2006-10-10 |
Ranbaxy Lab Ltd |
inibidores de fosfodiesterase do tipo iv, composição farmacêutica contendo os mesmos e processo para sua preparação
|
WO2005051931A2
(en)
*
|
2003-11-26 |
2005-06-09 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
MXPA06008240A
(es)
*
|
2004-01-21 |
2006-08-31 |
Schering Corp |
Metodos de tratamiento.
|
US20080009535A1
(en)
*
|
2004-08-30 |
2008-01-10 |
Sarala Balachandran |
Inhibitors of phosphodiesterase type-IV
|
US20060211667A1
(en)
*
|
2005-03-21 |
2006-09-21 |
Eric Marchewitz |
Use of pregnane steroid derivatives for enhancing physical performance
|
GB0507165D0
(en)
*
|
2005-04-08 |
2005-05-18 |
Glaxo Group Ltd |
Novel crystalline pharmaceutical product
|
ES2265276B1
(es)
|
2005-05-20 |
2008-02-01 |
Laboratorios Almirall S.A. |
Derivados de 4-(2-amino-1-hidroxietil)fenol como agonistas del receptor beta2 adrenergico.
|
GB0523653D0
(en)
*
|
2005-11-21 |
2005-12-28 |
Novartis Ag |
Organic compounds
|
US20070099883A1
(en)
*
|
2005-10-07 |
2007-05-03 |
Cheryl Lynn Calis |
Anhydrous mometasone furoate formulation
|
JP2009512677A
(ja)
*
|
2005-10-19 |
2009-03-26 |
ランバクシー ラボラトリーズ リミテッド |
ホスホジエステラーゼタイプiv阻害剤の組成物
|
AU2006305619A1
(en)
|
2005-10-19 |
2007-04-26 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions of muscarinic receptor antagonists
|
CN100389121C
(zh)
*
|
2005-12-09 |
2008-05-21 |
天津药业集团有限公司 |
糠酸莫美他松中间体21-羟的制备方法
|
CN100436473C
(zh)
*
|
2005-12-09 |
2008-11-26 |
天津药业集团有限公司 |
糠酸莫美他松中间体21-酯及制法
|
AR059216A1
(es)
*
|
2006-01-27 |
2008-03-19 |
Sun Pharmaceutical Ind Ltd |
11b-hidroxiandrosta-4-eno-3-onas
|
GB0615108D0
(en)
*
|
2006-07-28 |
2006-09-06 |
Glaxo Group Ltd |
Novel formulations
|
WO2008035316A2
(en)
*
|
2006-09-22 |
2008-03-27 |
Ranbaxy Laboratories Limited |
Phosphodiesterase inhibitors
|
CN101616901A
(zh)
*
|
2006-09-22 |
2009-12-30 |
兰贝克赛实验室有限公司 |
Iv型磷酸二酯酶的抑制剂
|
AU2007311607A1
(en)
*
|
2006-10-19 |
2008-04-24 |
Cipla Limited |
Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
|
US20080207659A1
(en)
*
|
2007-02-15 |
2008-08-28 |
Asit Kumar Chakraborti |
Inhibitors of phosphodiesterase type 4
|
EP2124943A1
(en)
*
|
2007-03-14 |
2009-12-02 |
Ranbaxy Laboratories Limited |
Pyrazolo [3, 4-b]pyridine derivatives as phosphodiesterase inhibitors
|
CN103497185A
(zh)
*
|
2007-03-14 |
2014-01-08 |
兰贝克赛实验室有限公司 |
用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物
|
WO2008126076A2
(en)
*
|
2007-04-11 |
2008-10-23 |
Perrigo Israel Pharmaceuticals Ltd. |
Low-dose mometasone formulations
|
MX2010002592A
(es)
*
|
2007-09-10 |
2010-03-30 |
Glenmark Pharmaceuticals Ltd |
Composicion farmaceutica topica para la combinacion de acido fusidico y corticoesteroides.
|
US20090082318A1
(en)
*
|
2007-09-26 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched mometasone
|
US8796248B2
(en)
*
|
2007-10-05 |
2014-08-05 |
Nektar Therapeutics |
Oligomer-corticosteroid conjugates
|
EP2111861A1
(en)
|
2008-04-21 |
2009-10-28 |
Ranbaxy Laboratories Limited |
Compositions of phosphodiesterase type IV inhibitors
|
ES2548402T3
(es)
|
2008-05-28 |
2015-10-16 |
Reveragen Biopharma, Inc. |
Moduladores esteroideos no hormonales de NF-kappaB para el tratamiento de enfermedades
|
UY32297A
(es)
|
2008-12-22 |
2010-05-31 |
Almirall Sa |
Sal mesilato de 5-(2-{[6-(2,2-difluoro-2-fenilitoxi) hexil]amino}-1-hidroxietil)-8-hidroxiquinolin-2( 1h)-ona como agonista del receptor b(beta)2 acrenérgico
|
EP2228368A1
(en)
|
2009-03-12 |
2010-09-15 |
Almirall, S.A. |
Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one
|
US8815258B2
(en)
|
2009-05-29 |
2014-08-26 |
Pearl Therapeutics, Inc. |
Compositions, methods and systems for respiratory delivery of two or more active agents
|
LT2435023T
(lt)
*
|
2009-05-29 |
2016-09-26 |
Pearl Therapeutics, Inc. |
Kompozicijos, skirtos ilgai veikiančių muskarininių antagonistų ir ilgai veikiančių beta-2-adrenerginio receptoriaus agonistų pristatymui į plaučius, ir susiję būdai bei sistemos
|
SG10201704847WA
(en)
|
2009-10-01 |
2017-07-28 |
Adare Pharmaceuticals Inc |
Orally administered corticosteroid compositions
|
WO2011093810A2
(en)
|
2010-01-28 |
2011-08-04 |
Bilgic Mahmut |
Dry powder pharmaceutical composition comprising tiotropium and mometasone
|
WO2011093815A2
(en)
|
2010-01-29 |
2011-08-04 |
Mahmut Bilgic |
Pharmaceutical compositions comprising formoterol and mometasone
|
US9198921B2
(en)
|
2010-04-05 |
2015-12-01 |
Reveragen Biopharma, Inc. |
Non-hormonal steroid modulators of NF-κB for treatment of disease
|
WO2011136754A1
(en)
|
2010-04-26 |
2011-11-03 |
Mahmut Bilgic |
A medicament developed for the treatment of respiratory diseases
|
JOP20120023B1
(ar)
|
2011-02-04 |
2022-03-14 |
Novartis Ag |
صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
|
EP2578570A1
(en)
|
2011-10-07 |
2013-04-10 |
Almirall, S.A. |
Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis.
|
WO2013109207A1
(en)
|
2012-01-16 |
2013-07-25 |
Mahmut Bilgic |
Dry powder formulations comprising mometasone
|
EP2641900A1
(en)
|
2012-03-20 |
2013-09-25 |
Almirall, S.A. |
Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor.
|
US10105316B2
(en)
|
2012-07-05 |
2018-10-23 |
Arven llac Sanayi Ve Ticaret A.S. |
Inhalation compositions comprising muscarinic receptor antagonist
|
US10111957B2
(en)
|
2012-07-05 |
2018-10-30 |
Arven Ilac Snayi ve Ticaret A.S. |
Inhalation compositions comprising glucose anhydrous
|
WO2014007770A2
(en)
|
2012-07-05 |
2014-01-09 |
Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi |
Inhalation compositions comprising corticosteroid and sorbitol
|
US20150224197A1
(en)
|
2012-07-05 |
2015-08-13 |
Arven Ilac Sanayi Ve Ticaret A.S. |
Inhalation compositions
|
CN105209013B
(zh)
|
2013-03-14 |
2019-04-26 |
诺华股份有限公司 |
喷雾干燥制剂经喷雾混合的脱非晶化
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
WO2014144894A1
(en)
|
2013-03-15 |
2014-09-18 |
Pearl Therapeutics, Inc. |
Methods and systems for conditioning of particulate crystalline materials
|
CA2912927A1
(en)
|
2013-05-22 |
2014-11-27 |
Pearl Therapeutics, Inc. |
Compositions, methods & systems for respiratory delivery of three or more active agents
|
WO2015034678A2
(en)
|
2013-09-06 |
2015-03-12 |
Aptalis Pharmatech, Inc. |
Corticosteroid containing orally disintegrating tablet compositions for eosinophilic esophagitis
|
RU2016141948A
(ru)
|
2014-03-27 |
2018-04-27 |
Новартис Аг |
Высушенные распылением дисперсии твердое-в-масле-в-воде активных фармацевтических ингредиентов для ингаляции
|
EP3006453A1
(en)
|
2014-10-08 |
2016-04-13 |
Cosmo Technologies Ltd. |
17alpha-monoesters and 17alpha,21-diesters of cortexolone for use in the treatment of tumors
|
WO2017004205A1
(en)
|
2015-06-29 |
2017-01-05 |
Reveragen Biopharma, Inc. |
NON-HORMONAL STEROID MODULATORS OF NF-κB FOR TREATMENT OF DISEASE
|
CN105481933B
(zh)
*
|
2015-12-25 |
2017-09-19 |
山东京卫制药有限公司 |
一种合成糠酸莫米松的方法
|
CN107266518B
(zh)
*
|
2016-04-08 |
2021-03-30 |
天津金耀集团有限公司 |
一种糠酸莫米松晶型及其制备方法
|
CN107266519B
(zh)
*
|
2016-04-08 |
2021-06-29 |
天津金耀集团有限公司 |
一种9β,11β-环氧-17α-羟基-16α-甲基-21-氯代-1,4孕甾二烯-3,20-二酮新晶型及其制备方法
|
TWI728172B
(zh)
|
2016-08-18 |
2021-05-21 |
美商愛戴爾製藥股份有限公司 |
治療嗜伊紅性食道炎之方法
|
CN107778341A
(zh)
*
|
2016-08-30 |
2018-03-09 |
天津太平洋制药有限公司 |
一种哈西奈德的制备方法
|
CN107793462A
(zh)
*
|
2016-08-30 |
2018-03-13 |
天津太平洋制药有限公司 |
一种丙酸氯倍他索的制备方法
|
CN109206468B
(zh)
*
|
2017-06-30 |
2023-06-27 |
天津药业研究院股份有限公司 |
一种糠酸莫米松的制备方法
|
CN109206466B
(zh)
*
|
2017-06-30 |
2022-08-09 |
天津药业研究院股份有限公司 |
一种甾体21位羟基氯代或溴代方法
|
CN107573398B
(zh)
*
|
2017-09-07 |
2021-02-26 |
山东泰华生物科技股份有限公司 |
一种哈西奈德及其衍生物的制备方法
|
CN108395465B
(zh)
*
|
2018-05-10 |
2019-07-30 |
浙江仙居仙乐药业有限公司 |
一种地塞米松环氧水解物的合成方法
|
US11382922B2
(en)
|
2019-03-07 |
2022-07-12 |
Reveragen Biopharma, Inc. |
Aqueous oral pharmaceutical suspension compositions
|
IL309888A
(en)
|
2021-07-09 |
2024-03-01 |
Astrazeneca Pharmaceuticals Lp |
Aerosol drug delivery compounds, methods and systems
|
WO2023119093A1
(en)
|
2021-12-20 |
2023-06-29 |
Astrazeneca Ab |
Compositions, methods and systems for aerosol drug delivery
|